Key facts
- ClicBio’s last known valuation is $39.6M (Dec 2025).
- It has raised $16.9M; the latest was Seed Round ($16.9M) in Dec 2025.
- Notable investors include University of California, Medical Excellence Capital, San Diego.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for ClicBio
- ·The full record, as it builds
Funding rounds
No funding rounds for ClicBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ClicBio
Operator of metabolic therapy drugs intended to regulate appetite and treat obesity through modulation of hunger pathways. The company offers small-molecule inhibitors targeting appetite-regulating neurons and supporting energy balance and anti-inflammatory effects, enabling patients with metabolic disorders to manage weight and improve metabolic health.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Website
- clicbiotech.com/
- Ownership
- Privately Held (backing)
ClicBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ClicBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ClicBio in its N-PORT filings yet. We sweep new filings monthly.